Screening for occult malignancy using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in patients with unprovoked venous thromboembolism - 29BRC20.0021

Centre Hospitalier Regional Et Universitaire De Brest0 sites638 target enrollmentStarted: May 24, 2024Last updated: July 22, 2024

Conditions

Trial Snapshot

No summary available.

•Patients aged 50 years or older with a new diagnosis of first unprovoked proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) = 4 weeks as detailed below will be eligible to participate into the study., No recent paralysis, paresis, or prolonged immobilization> 3 days for acute medical condition or plaster cast of the lower limbs in the last 3 months., No major surgery (within the past 3 months) requiring general or regional anaesthesia, No biological or clinical thrombophilia, No active malignancy (known malignancy, progressive and/or treated during the last 5 years) except for adequately treated basal or squamous cell carcinoma. Patients whose state of health suggests the presence of cancer at the time of diagnosis of VTE cannot be included in the protocol.

•Hypersensitivity to 18F-FDG or any of the excipients according to the product monograph, Unavailable to follow-up, VTE while on anticoagulation (e.g apixaban, rivaroxaban, edoxaban, dabigatran, warfarin), VTE provoked by a major inherited or acquired risk factor, Refusal or inability to provide informed consent, Life expectancy <12 months, Ongoing pregnancy, Vulnerable individuals (Persons deprived of their liberty by judicial or administrative decision; Persons under psychiatric care under duress; Persons admitted to a health or social institution for purposes other than research; Persons of full age subject to a legal protection measure; persons under protective custody)

Sponsor